INTRODUCTION
============

Right-sided endocarditis (RSE) accounts for 5%--10% of all cases of infective endocarditis (IE) and most frequently involves the tricuspid valve.[@b1-rmmj-10-1-e0003],[@b2-rmmj-10-1-e0003] At-risk populations include intravenous drug users (IVDU) and patients who have undergone intravenous catheterization. Other risk factors are alcohol abuse, immunodeficiency, and congenital heart defects.[@b3-rmmj-10-1-e0003]--[@b7-rmmj-10-1-e0003]

Patients with RSE may be classified into three groups: (1) IVDU; (2) cardiac device carriers; and (3) no left-sided endocarditis (LSE), no IVDU, and no cardiac device. Each group can be considered as independent entities due to the relevant epidemiologic, clinical, microbiological, echocardiographic, and prognostic differences among them.[@b8-rmmj-10-1-e0003]

The most common pathogenic cause of RSE is *Staphylococcus aureus*, among both IVDU and the rest of the patient population.[@b1-rmmj-10-1-e0003],[@b9-rmmj-10-1-e0003]--[@b13-rmmj-10-1-e0003] Other RSE-causing pathogens are coagulase-negative staphylococci and Gram-negative bacilli; there are also cases with polymicrobial involvement.[@b9-rmmj-10-1-e0003],[@b12-rmmj-10-1-e0003],[@b14-rmmj-10-1-e0003] The pathogenesis of RSE is unclear. Several mechanisms have been proposed: direct injection of the pathogen into the venous blood stream followed by an encounter with the tricuspid valve, immunological mechanisms, and endothelial injury.[@b15-rmmj-10-1-e0003],[@b16-rmmj-10-1-e0003]

The clinical presentation of RSE often involves fever accompanied by respiratory signs and symptoms secondary to septic emboli to the lungs.[@b3-rmmj-10-1-e0003],[@b4-rmmj-10-1-e0003],[@b17-rmmj-10-1-e0003] Due to this unique clinical presentation the diagnosis of RSE is often delayed.[@b18-rmmj-10-1-e0003] Hence, a strong clinical suspicion must be present in order to establish a diagnosis.[@b18-rmmj-10-1-e0003]--[@b20-rmmj-10-1-e0003]

The aims of this study were to evaluate the epidemiologic, clinical, and laboratory characteristics of RSE with regard to patients, etiology, and pathogenesis, as compared with LSE, and to evaluate and compare the patient outcomes for RSE versus LSE.

Since Israeli demographics are quite different from those of the Unites States and Europe with regard to intravenous drug abuse and rheumatic valvular disease prevalence, this study has potential importance for the treatment of RSE and LSE patients in Israel.

MATERIALS AND METHODS
=====================

The study focused on IE patients admitted to Soroka University Medical Center (SUMC). The center is the only tertiary hospital for a population of 1.1 million, geographically spread out through an area half the size of the State of Israel.

Institutional Review Board approval was obtained prior initiation of the study. A retrospective cohort study was performed of all adult patients with RSE hospitalized in SUMC between 2003 and 2013, since all medical records were computerized in 2003, making the data easily accessible.

Discharge diagnoses (ICD-9) were used to identify subjects with infective endocarditis according to ICD-9 codes: 112.81, 397, 421.0-421.9, 424, 424.2, 424.9.

All IE cases were reviewed by two investigators (senior physicians in internal medicine) according to the modified Duke criteria for IE diagnosis.[@b20-rmmj-10-1-e0003]

The patients' demographic characteristics, ICD-9 diagnoses, medications, and clinical and laboratory data were obtained from a comprehensive medical chart review and from the computerized hospital database.

Patients with RSE were compared to patients with LSE. In-hospital mortality (primary outcome), duration of hospitalization, recurrent hospitalization, recurrent infective endocarditis, and one-year mortality (secondary outcomes) were obtained.

Data were expressed as mean ± standard deviation (SD), median ± interquartile range (IQR), or number and percentage. Comparison of RSE and LSE patient characteristics was performed using *t* test, chi-square, and non-parametric tests. Survival curves were calculated by the Kaplan--Meier method, and comparison between patient groups was performed by log-rank test. A two-sided *P* value \<0.05 was considered as statistically significant.

RESULTS
=======

The study included 215 patients diagnosed with IE based on the modified Duke criteria. Of these, 176 had LSE and 39 had RSE.

Patient demographic and clinical characteristics are detailed in [Table 1](#t1-rmmj-10-1-e0003){ref-type="table"}. The majority of patients were male (total of 132 men and 44 women across both groups). The percentage of men and women in both groups was similar. Patients with RSE were younger than patients with LSE (48.1±18.9 years versus 61.8±17.0 years, *P*\<0.001).

###### 

Comparison of Epidemiologic, Clinical, and Laboratory Characteristics of Patients with Left- and Right-sided Endocarditis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                                                                         Right-sided Endocarditis\   Left-sided Endocarditis\   *P* value
                                                                                     *n*=39                      *n*=176                    
  ---------------------------------------------------------------------------------- --------------------------- -------------------------- -----------
  Age, mean±SD                                                                       48.1±18.9                   61.8±17.0                  \<0.001

                                                                                                                                            

  Male sex, *n* (%)                                                                  28 (71.8)                   104 (59.1)                 0.1

                                                                                                                                            

  IV drug user, *n* (%)                                                              17 (43.6)                   7 (4.0)                    \<0.001

                                                                                                                                            

  Endocarditis in the past, *n* (%)                                                  6 (15.4)                    5 (2.8)                    0.006

                                                                                                                                            

  Cardiac pacemaker, *n* (%)                                                         8 (20.5)                    23 (13.1)                  0.3

                                                                                                                                            

  Inflammatory reaction after cardiac device, prosthetic valve, and graft, *n* (%)   6 (15.4)                    64 (36.4)                  0.01

                                                                                                                                            

  Congestive heart failure, *n* (%)                                                  6 (15.4)                    27 (15.3)                  1

                                                                                                                                            

  Diabetes mellitus, *n* (%)                                                         7 (17.9)                    50 (28.4)                  0.2

                                                                                                                                            

  Malignancy, *n* (%)                                                                8 (20.5)                    22 (12.5)                  0.5

                                                                                                                                            

  Chronic pulmonary disease, *n* (%)                                                 1 (2.6)                     20 (11.4)                  0.1

                                                                                                                                            

  Connective tissue disease, *n* (%)                                                 none                        6 (3.4)                    0.5

                                                                                                                                            

  Chronic liver disease, *n* (%)                                                     7 (17.9)                    3 (1.7)                    \<0.001

                                                                                                                                            

  Cardiac arrhythmias, *n* (%)                                                       8 (20.8)                    68 (38.6)                  0.04

                                                                                                                                            

  Rheumatic heart disease                                                            3 (7.7)                     33 (18.8)                  0.1

                                                                                                                                            

  Rheumatoid factor (IU/mL), median (IQR)                                            17 (11;68)                  35 (12;90)                 0.09

                                                                                                                                            

  C-reactive protein (mg/L), median (IQR)                                            17 (6;32)                   7.3 (4.7;11.5)             0.008

                                                                                                                                            

  C3 (mg%), median (IQR)                                                             116 (76;140)                129 (105;146)              0.4

                                                                                                                                            

  C4 (mg%), median (IQR)                                                             26 (12;28)                  29 (23;35)                 0.09

                                                                                                                                            

  Surgery, *n* (%)                                                                   9 (23.1)                    47 (26.8)                  0.7

                                                                                                                                            

  **Type of Surgery**                                                                                                                       

   AVR, *n* (%)                                                                      none                        16 (9.1)                   0.04

                                                                                                                                            

   MVR, *n* (%)                                                                      none                        17 (9.7)                   0.04

                                                                                                                                            

   Pacemaker lead extraction, *n* (%)                                                3 (7.7)                     7 (4.0)                    0.3

                                                                                                                                            

   Pacemaker extraction, *n* (%)                                                     1 (2.6)                     2 (1.1)                    0.4

                                                                                                                                            

   TVR/tricuspid valve excision, *n* (%)                                             2 (5.1)                     none                       0.03

                                                                                                                                            

   Triple valve surgery (AVR+MVR+TVR), *n* (%)                                       1 (2.6)                     1 (0.6)                    0.3

                                                                                                                                            

   Double valve surgery (AVR+MVR), *n* (%)                                           none                        3 (1.7)                    1

                                                                                                                                            

   Double valve surgery (MVR+TVR), *n* (%)                                           none                        1 (0.6)                    1

                                                                                                                                            

  **Main Cause of Admission**                                                                                                               

                                                                                                                                            

   Fever, *n* (%)                                                                    27 (69.2)                   115 (65.3)                 0.7

                                                                                                                                            

   Chest pain, *n* (%)                                                               2 (5.1)                     4 (2.3)                    0.3

                                                                                                                                            

   Heart failure, *n* (%)                                                            3 (7.7)                     12 (6.8)                   0.7

                                                                                                                                            

   Weakness, anemia, *n* (%)                                                         none                        9 (5.1)                    0.4

                                                                                                                                            

   Stroke, *n* (%)                                                                   none                        7 (4.0)                    0.4

                                                                                                                                            

   Abnormal echocardiography, *n* (%)                                                none                        7 (4.0)                    0.4

                                                                                                                                            

   Infected pacemaker pocket, *n* (%)                                                2 (5.1)                     none                       0.03

                                                                                                                                            

   Weight loss, *n* (%)                                                              none                        4 (2.3)                    1

                                                                                                                                            

   Cough and hemoptysis, *n* (%)                                                     1 (2.6)                     1 (0.6)                    0.3

                                                                                                                                            

   Other, *n* (%)                                                                    4 (10.3)                    15 (8.5)                   0.8
  -----------------------------------------------------------------------------------------------------------------------------------------------------

AVR, aortic valve replacement; IV, intravenous; IQR, interquartile range; MVR, multiple valve replacement; SD, standard deviation; TVR, tricuspid valve replacement.

Among the RSE patients there were more IVDU (43.6% versus 4.0%, *P*\<0.001) and more patients with a prior IE episode (15.4% versus 2.8%, *P*= 0.006). More LSE patients suffered from cardiac arrhythmia (38.6% versus 20.8%, *P*\<0.04), whereas more RSE patients suffered from chronic liver diseases (17.9% versus 1.7%, *P*\<0.001).

There were no statistically significant differences between the two groups in most laboratory parameters, except for an elevated C-reactive protein (CRP) in the RSE group (17 \[IQR 6;32\] mg/L versus 7.3 \[4.7;11.5\] mg/L, *P*\<0.008).

With regard to the reason for hospital admission, more RSE patients were admitted due to an infected pacemaker pocket (5.1% versus none, *P*=0.03). However, there were more cases of inflammatory reactions after cardiac device, prosthetic valve, and grafts in the LSE group (36.4% versus 15.4%, *P*=0.01).

The etiologic factors for RSE and LSE are presented in [Table 2](#t2-rmmj-10-1-e0003){ref-type="table"}. The most common pathogen in both groups was *Staphylococcus aureus*, which occurred in more than half of the RSE group (51%) as compared to the LSE group (19%).

###### 

Etiologic Factors of Left- and Right-sided Endocarditis.

  ----------------------------------------------------------------------------------------------------------------
  Etiology                                      Right-sided Endocarditis\   Left-sided Endocarditis\   *P* value
                                                *n*=39                      *n*=176                    
  --------------------------------------------- --------------------------- -------------------------- -----------
  *Staphylococcus aureus*, *n* (%)              20 (51.3)                   33 (18.8)                  \<0.001

  Staphylococci, coagulase-negative, *n* (%)    none                        24 (13.6)                  0.009

  Streptococci, viridans, *n* (%)               4 (10.3)                    26 (14.8)                  0.6

  Streptococci, other types, *n* (%)            3 (7.7)                     13 (7.4)                   1

  HACEK group, *n* (%)                          none                        8 (4.5)                    0.3

  Gram-negative rods, *n* (%)                   2 (5.1)                     4 (2.3)                    0.3

  Enterococcus, *n* (%)                         1 (2.6)                     23 (13.1)                  0.08

  Fungi, *n* (%)                                1 (2.6)                     2 (1.1)                    0.4

  Pseudomonas, *n* (%)                          none                        4 (2.3)                    1

  Brucella, *n* (%)                             none                        3 (1.7)                    1

  Q-fever, *n* (%)                              none                        3 (1.7)                    1

  Unknown pathogen, culture-negative, *n* (%)   8 (20.5)                    30 (17)                    0.6
  ----------------------------------------------------------------------------------------------------------------

HACEK, *Haemophilus aphrophilus*, *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*.

There were no statistically significant differences in the pathologic findings of either group on transesophageal echocardiography ([Table 3](#t3-rmmj-10-1-e0003){ref-type="table"}).

###### 

Echocardiographic Findings on Transesophageal Echocardiography.

  Echocardiographic Findings                              Right-sided Endocarditis*n*=39   Left-sided Endocarditis*n*=176   *P* value
  ------------------------------------------------------- -------------------------------- -------------------------------- -----------
  Vegetation, *n* (%)                                     23 (59)                          99 (56.3)                        0.8
  Abscess, *n* (%)                                        1 (2.6)                          2 (1.1)                          0.4
  Mass attached to electrode of the pacemaker, *n* (%)    2 (5.1)                          8 (4.5)                          1
  New severe valvular insufficiency, *n* (%)              1 (2.6)                          4 (2.3)                          1
  Prosthetic valve dehiscence, *n* (%)                    none                             1 (.6)                           1
  Absence of findings typical for endocarditis, *n* (%)   12 (30.8)                        61 (34.7)                        0.7

In-hospital mortality rates were lower among patients with RSE (2.6% versus 17%, *P*\<0.037), as shown in [Figure 1](#f1-rmmj-10-1-e0003){ref-type="fig"} and [Table 4](#t4-rmmj-10-1-e0003){ref-type="table"}. There were no statistically significant differences in other outcomes between the two groups of patients. One-year survival curves for RSE and LSE are shown in [Figure 2](#f2-rmmj-10-1-e0003){ref-type="fig"}.

![Kaplan--Meier In-hospital Survival Curves Stratified by Endocarditis with Left- and Right-side Involvement\
Log-rank test *P*=0.023.](rmmj-10-1-e0003-g001){#f1-rmmj-10-1-e0003}

###### 

Outcomes of Patients with Left- and Right-sided Endocarditis.

  Parameters                              Right-sided Endocarditis*n*=39   Left-sided Endocarditis*n*=176   *P* value
  --------------------------------------- -------------------------------- -------------------------------- -----------
  Recurrences of endocarditis, *n* (%)    4 (10.3)                         20 (11.4)                        1
  Recurrent hospitalization, *n* (%)      5 (12.5)                         17 (9.7)                         0.5
  In-hospital mortality, *n* (%)          1 (2.6)                          30 (17)                          0.037
  One-year mortality, *n* (%)             2 (5.1)                          22 (12.5)                        0.2
  Length of hospital stay, median (IQR)   31 (18;45)                       27 (15;42)                       0.08

![Kaplan--Meier One-year Survival Curves Stratified by Endocarditis with Left- and Right-side Involvement\
Log-rank test *P*=0.015.](rmmj-10-1-e0003-g002){#f2-rmmj-10-1-e0003}

DISCUSSION
==========

Right-sided endocarditis is less common than LSE. In this study, 18.1% of patients with IE presented with RSE, which was comparable to historical data.[@b1-rmmj-10-1-e0003],[@b2-rmmj-10-1-e0003] However, RSE is common among IVDU; 86% of IE cases among IVDU present with RSE.[@b21-rmmj-10-1-e0003] In our study 70% of RSE patients and 4% of LSE patients were IVDU. Another significant source of RSE is a pacemaker lead infection. In our study a significant number of patients had had a cardiac or another surgical intervention. Our data confirmed that pacemaker lead infection has become a significant risk factor for IE and specifically for RSE.

According to a previous publication, RSE patients are younger as compared to LSE patients.[@b22-rmmj-10-1-e0003] Our study confirmed this finding. The higher percentage of RSE patients with recurrent endocarditis as compared to the LSE group is probably due to the increased prevalence of IVDU in the former population.

The pathogeneses of RSE and LSE are known to be different.[@b15-rmmj-10-1-e0003],[@b16-rmmj-10-1-e0003] The literature describes several pathogenetic mechanisms that differentiate between the two types of IE: not only the primary contact of the injected substance with the tricuspid valve in RSE, but also intimal damage and thrombus formation, cocaine-induced endothelial damage with secondary pulmonary hypertension, valvular damage and infection, pressure gradient and turbulence,[@b15-rmmj-10-1-e0003],[@b22-rmmj-10-1-e0003],[@b23-rmmj-10-1-e0003] changes in the valvular endothelium,[@b24-rmmj-10-1-e0003] and different cytokine expression.[@b25-rmmj-10-1-e0003] In our study, RSE patients had a significantly more prominent CRP elevation. Elevations of CRP occur in association with acute and chronic inflammation due to a range of causes, including infectious diseases and non-infectious inflammatory disorders. Markedly elevated CRP levels are strongly associated with bacterial infection.[@b26-rmmj-10-1-e0003] Acute inflammation generally shows a marked CRP response, while low-grade inflammation shows only a minor CRP elevation. The inflammatory response to infection and tissue injury supports host defense, clearance of necrotic tissue, adaptation, and repair, while the purpose of low-grade inflammation appears to be restoration of metabolic homeostasis.[@b27-rmmj-10-1-e0003] The increased CRP levels found in RSE patients in our study may be due to their young age, resulting in a more prominent inflammatory response, and the respiratory injury, particularly pulmonary parenchyma, often seen in RSE patients as compared to LSE patients. This requires further investigation and research.

It is not surprising that for RSE patients, the majority of whom are IVDU, the percentage of patients with chronic liver diseases is higher, perhaps reflecting the higher rates of hepatitis B and hepatitis C infections and alcohol abuse in this population.

The most common pathogen in both groups of patients in our study was *Staphylococcus aureus*, consistent with previous data.[@b1-rmmj-10-1-e0003],[@b9-rmmj-10-1-e0003],[@b12-rmmj-10-1-e0003],[@b28-rmmj-10-1-e0003] It was found in more than half of the RSE group, as compared to less than 20% in the LSE group. The absence of coagulase-negative staphylococci in the RSE group was also notable in our study. These etiologic differences are important for management of patients with IE in our region.

The in-hospital mortality in our study was significantly lower in RSE patients as compared to LSE patients. One-year mortality was also lower in RSE groups compared to LSE groups, but did not reach statistical significance. These results are also similar to previous studies.[@b29-rmmj-10-1-e0003] It is known that the prognosis of RSE is better than for LSE, possibly due to the younger age of the RSE patients, and tricuspid valve involvement has few hemodynamic consequences compared to mitral valve dysfunction.[@b22-rmmj-10-1-e0003],[@b29-rmmj-10-1-e0003] The majority of RSE patients responded well to appropriate antibiotic therapy without complications and with no spread beyond the borders of the involved valve.[@b30-rmmj-10-1-e0003],[@b31-rmmj-10-1-e0003] Very few RSE patients need operative treatment of the involved valve.[@b21-rmmj-10-1-e0003],[@b32-rmmj-10-1-e0003]--[@b34-rmmj-10-1-e0003] In our study only a minority of patients in both groups required operative treatment.

The results of this study have demonstrated a difference in the characteristics of RSE patients in our study versus previous studies, i.e. a documented higher percentage of patients with pacemaker lead infection and fewer who were IVDU. Indeed, intravenous drug abuse in Israel is less common. Pacemaker lead infection is the leading cause of RSE in Southern Israel. Due to the increased use of these devices, a high index of suspicion is needed so as to diagnose RSE at-risk patients with appropriate clinical presentations.

Another interesting finding of our study was that a mass attached to the electrode was just as common in LSE, indicating that sometimes left- and right-sided endocarditis can occur simultaneously.

The major limitations of this study are that it was a single-center investigation and that it used ICD codes to identify patients. However, patients were analyzed over a 10-year period.

CONCLUSION
==========

Our study demonstrated an increasing percentage of RSE compared to LSE among patients with IE in Southern Israel. This trend is expected to continue due to the increasing number of patients undergoing device insertion. Pacemaker lead infection has become the leading cause of RSE in Southern Israel; it is much less common to find RSE in IVDU. This study has also demonstrated etiological and clinical differences between RSE and LSE, with the RSE prognosis being better compared to LSE.
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